Prognostic model based on magnetic resonance imaging, whole-tumour apparent diffusion coefficient values and HPV genotyping for stage IB-IV cervical cancer patients following chemoradiotherapy
To develop and validate a prognostic model of integrating whole-tumour apparent diffusion coefficient (ADC) from pretreatment diffusion-weighted (DW) magnetic resonance (MR) imaging with human papillomavirus (HPV) genotyping in predicting the overall survival (OS) and disease-free survival (DFS) for women with stage IB–IV cervical cancer following concurrent chemoradiotherapy (CCRT).
We retrospectively analysed three prospectively collected cohorts comprising 300 patients with stage IB–IV cervical cancer treated with CCRT in 2007–2014 and filtered 134 female patients who underwent MR imaging at 3.0 T for final analysis (age, 24–92 years; median, 54 years). Univariate and multivariate Cox regression analyses were used to evaluate the whole-tumour ADC histogram parameters, HPV genotyping and relevant clinical variables in predicting OS and DFS. The dataset was randomly split into training (n = 88) and testing (n = 46) datasets for construction and independent bootstrap validation of the models.
The median follow-up time for surviving patients was 69 months (range, 9–126 months). Non-squamous cell type, ADC10 <0.77 × 10-3 mm2/s, T3-4, M1 stage and high-risk HPV status were selected to generate a model, in which the OS and DFS for the low, intermediate and high-risk groups were significantly stratified (p < 0.0001). The prognostic model improved the prediction significantly compared with the International Federation of Gynaecology and Obstetrics (FIGO) stage for both the training and independent testing datasets (p < 0.0001).
The prognostic model based on integrated clinical and imaging data could be a useful clinical biomarker to predict OS and DFS in patients with stage IB–IV cervical cancer treated with CCRT.
• ADC 10 is the best prognostic factor among ADC parameters in cervical cancer treated with CCRT
• A novel prognostic model was built based on histology, ADC 10 , T and M stage and HPV status
• The prognostic model outperforms FIGO stage in the survival prediction
KeywordsCervical cancer Human papillomavirus Chemoradiotherapy Diffusion magnetic resonance imaging Prognosis
International Federation of Gynaecology and Obstetrics
Squamous cell carcinoma antigen
Supported by Chang Gung Medical Foundation grant CIRPG3E0022, CMRPG3F2241; National Science Council (Taiwan) MOST 104-2314-B-182A-095-MY3, NMRPD1E1051-3; Chang Gung IRB 95-1243B, 97-2366B, 102-0620A3 and 104-8300B. The authors acknowledge the assistance provided by the Cancer Center and the Clinical Trial Center, Chang Gung Memorial Hospital, Linkou, Taiwan, which was founded by the Ministry of Health and Welfare of Taiwan MOHW106-TDU-B-212-113005.
Compliance with ethical standards
The scientific guarantor of this publication is Chyong-Huey Lai.
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
Lan-Yan Yang, PhD. kindly provided statistical advice for this manuscript.
Written informed consent was obtained from all subjects (patients) in this study.
Institutional Review Board approval was obtained.
• diagnostic or prognostic study
• performed at one institution
- 1.American Cancer Society: cancer facts and figures (2018) American Cancer Society. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2018/cancer-facts-and-figures-2018.pdf. Accessed 27 June 2018
- 2.NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. National Comprehensive Cancer Network Web site. https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf. Accessed 27 June 2018
- 4.Wang CC, Lai CH, Huang HJ et al (2010) Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy. Int J Radiat Oncol Biol Phys 78:1111-1120Google Scholar
- 7.Heo SH, Shin SS, Kim JW et al (2013) Pre-treatment diffusion-weighted MR imaging for predicting tumor recurrence in uterine cervical cancer treated with concurrent chemoradiation: value of histogram analysis of apparent diffusion coefficients. Korean J Radiol 14:616-625Google Scholar
- 10.Himoto Y, Fujimoto K, Kido A et al (2015) Pretreatment mean apparent diffusion coefficient is significantly correlated with event-free survival in patients with International Federation of Gynecology and Obstetrics stage Ib to IIIb cervical cancer. Int J Gynecol Cancer 25:1079–1085CrossRefGoogle Scholar
- 14.Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures. they are data. Radiology 278:563–577Google Scholar
- 22.Jalaguier-Coudray A, Villard-Mahjoub R, Delouche A et al (2017) Value of dynamic contrast-enhanced and diffusion-weighted MR imaging in the detection of pathologic complete response in cervical cancer after neoadjuvant therapy: a retrospective observational study. Radiology. https://doi.org/10.1148/radiol.2017161299:161299
- 23.Marur S, Li S, Cmelak AJ et al (2017) E1308: Phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group. J Clin Oncol 35:490–497CrossRefGoogle Scholar
- 35.Ueno Y, Lisbona R, Tamada T, Alaref A, Sugimura K, Reinhold C (2017) Comparison of FDG PET metabolic tumour volume versus ADC histogram: prognostic value of tumour treatment response and survival in patients with locally advanced uterine cervical cancer. Br J Radiol 90:20170035CrossRefGoogle Scholar